Latest Notice Heajin Kim 2/19/25 Latest Notice Heajin Kim 2/19/25 Luxa’s Expanded Access Policy Read More press release Heajin Kim 2/19/25 press release Heajin Kim 2/19/25 Luxa Biotechnology Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to RPESC-RPE-4W Transplantation for the Treatment of Dry Age-Related Macular Degeneration Read More Heajin Kim 10/1/24 Heajin Kim 10/1/24 Read More press release Heajin Kim 10/1/24 press release Heajin Kim 10/1/24 Luxa Biotechnology LLC Appoints Keith E. Dionne, Ph.D., as Chief Executive Officer Read More Latest Notice Mediaspace 5/2/24 Latest Notice Mediaspace 5/2/24 Read More Newer Posts Older Posts
Latest Notice Heajin Kim 2/19/25 Latest Notice Heajin Kim 2/19/25 Luxa’s Expanded Access Policy Read More
press release Heajin Kim 2/19/25 press release Heajin Kim 2/19/25 Luxa Biotechnology Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to RPESC-RPE-4W Transplantation for the Treatment of Dry Age-Related Macular Degeneration Read More
press release Heajin Kim 10/1/24 press release Heajin Kim 10/1/24 Luxa Biotechnology LLC Appoints Keith E. Dionne, Ph.D., as Chief Executive Officer Read More
